Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Valeritas Holdings Inc. VLRXQ

Healthcare
Valeritas Holdings Inc is a commercial-stage medical technology company. It is engaged in the business of improving health and simplifying life for diabetic patients by developing and commercializing innovative technologies. The company designed its first commercialized product, the V-Go Wearable Insulin Delivery Device, or V-Go, that supports the patients with Type 2 diabetes who need insulin... see more

Recent & Breaking News (OTCPK:VLRXQ)

Valeritas Receives Court Approval of Sale of Business to Zealand Pharma

PR Newswire March 20, 2020

Valeritas Experiences a Temporary Supply Disruption Resulting in Revised Preliminary Financial Results for 2019 Fourth Quarter and Full Year

GlobeNewswire December 20, 2019

Valeritas' V-Go® Wearable Insulin Delivery Device Demonstrates Reductions in A1c and Daily Insulin Usage

GlobeNewswire November 15, 2019

Valeritas Announces Third Quarter 2019 Financial Results

GlobeNewswire November 12, 2019

Valeritas Presents Positive h-Patch(TM) Apomorphine Study Data at the World Congress of Neurology (WCN 2019)

GlobeNewswire October 29, 2019

Valeritas to Report Third Quarter 2019 Financial Results on November 12, 2019

GlobeNewswire October 24, 2019

GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with Valeritas Proprietary h-Patch(TM) Wearable Device in Preclinical Study

GlobeNewswire October 21, 2019

Valeritas Presents Positive h-Patch(TM) Apomorphine Study Data at Global Experts Meeting on Frontiers in Alzheimer's Disease & Dementia

GlobeNewswire October 15, 2019

Valeritas Announces Poster Presentation of Preclinical h-Patch(TM) Cannabidiol (CBD) Study at the American Epilepsy Society's Annual Meeting

GlobeNewswire October 10, 2019

Valeritas Announces Poster Presentation of Preclinical h-Patch(TM) Apomorphine Study at the World Congress of Neurology (WCN 2019)

GlobeNewswire October 8, 2019

Valeritas Hosts Educational Symposium and Participates in the Metabolic & Endocrine Disease Summit (MEDS) East

GlobeNewswire October 3, 2019

Valeritas Reduces its Long-Term Debt Obligation Nearly 60% by Exchanging $25.0 Million of Debt for Series B Convertible Preferred Stock

GlobeNewswire October 2, 2019

Valeritas Announces Participation on "The Cutting Edge of Cannabinoid Science" Panel at the CBD Expo EAST Conference

GlobeNewswire September 26, 2019

Valeritas Presents Positive h-Patch(TM) CBD Study Data at CannMed Conference

GlobeNewswire September 24, 2019

Valeritas Announces Presentation of Preclinical h-Patch(TM) CBD Study at CannMed Conference

GlobeNewswire September 19, 2019

Valeritas Presents Positive CBD h-Patch(TM) Data at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

GlobeNewswire September 12, 2019

Valeritas Announces Oral Presentation of Preclinical h-Patch(TM) CBD Study at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

GlobeNewswire September 3, 2019

Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire August 29, 2019

Clinical Trial Evaluating Delivery of Regular Human Insulin vs. Rapid Acting Insulin Delivered by Valeritas' V-Go® Meets Primary A1c Endpoint

GlobeNewswire August 15, 2019

Valeritas Announces Second Quarter 2019 Financial Results

GlobeNewswire August 8, 2019